MF59C.1 Adjuvant

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV Infections

Phase 1

Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials

CompletedNCT01376726

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2011-07-31End: 2014-12-31Updated: 2021-10-15

Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)

CompletedNCT01423825

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2011-08-31End: 2013-07-31Updated: 2021-10-14

Related Papers

Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap

Clinical and Vaccine Immunology2016-04-2128 citations